According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …
Filed under: Uncategorized | Tagged: cost, enzalutamide, hearing, price, Xtandi | 11 Comments »
The Appropriations Defense subcommittee of the U.S. House of Representatives is to convene a hearing tomorrow (May 20, 2010), featuring public testimony regarding prostate cancer research within the Congressionally Directed Medical Research Program (CDMRP). … READ MORE …
Filed under: Uncategorized | Tagged: CDMRP, funding, hearing, Prostate Cancer Research Program | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 